Phosphonate-Chloroquine Conjugates for Bone-Targeted Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for osteoporosis and inflammatory bone diseases, such as rheumatoid arthritis, are limited by poor patient compliance, side effects, and inadequate delivery of therapeutic agents to bone tissue, leading to suboptimal therapeutic outcomes and unmet needs for improved efficacy and new approaches.
Innovation Solution
Development of Bone-Targeted Chloroquine (BTCQ) analogs that conjugate chloroquine to a phosphonate moiety via a linker, allowing for controlled local delivery to bone tissue, thereby enhancing anti-resorptive effects and reducing systemic adverse effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bisphosphonates are used to treat osteoporosis, then bone loss is prevented and fractures are reduced, but patient compliance is poor and side effects occur
Solution Approach 1:
The patent modifies the chemical structure of bisphosphonates by conjugating them with chloroquine through a linker, creating a new compound with altered pharmacokinetic properties. This structural parameter change aims to improve therapeutic efficacy while reducing side effects and improving compliance.
Solution Approach 2:
The invention creates a composite molecular structure combining two therapeutic agents (bisphosphonate and chloroquine) into a single conjugate molecule. This composite approach allows simultaneous delivery of both drugs with synergistic effects, addressing multiple therapeutic needs while improving patient compliance.
2Reliability
If chloroquine is used to prevent bone resorption, then anti-resorptive effects are achieved, but systemic toxicity occurs
Solution Approach 1:
The bisphosphonate-chloroquine conjugate exhibits local targeting to bone tissue through the bisphosphonate moiety, which has high affinity for hydroxyapatite in bone. This local concentration of the drug at the target site enhances anti-resorptive activity while minimizing systemic exposure and toxicity.
Solution Approach 2:
The linker in the conjugate acts as an intermediary that connects the bone-targeting bisphosphonate to the therapeutic chloroquine. This intermediary structure allows the chloroquine to be delivered specifically to bone tissue via the bisphosphonate anchor, reducing systemic distribution and toxicity.
3Object-affected harmful factors
If hydroxychloroquine is used instead of chloroquine, then toxicity is reduced, but anti-resorptive effects are lost
Solution Approach 1:
The patent uses chloroquine (which has proven anti-resorptive activity) conjugated to bisphosphonate, creating a new compound with modified pharmacokinetic parameters. This parameter change allows retention of anti-resorptive efficacy while the bone-targeting mechanism reduces systemic toxicity compared to unconjugated chloroquine.
4Quantity of substance
If therapeutic agents are delivered systemically, then widespread coverage is achieved, but delivery to bone tissue is inadequate
Solution Approach 1:
The bisphosphonate moiety in the conjugate provides localized targeting to bone tissue through its high affinity for hydroxyapatite. This creates a non-uniform distribution pattern where the drug is concentrated at the bone site rather than being evenly distributed systemically, improving delivery precision to the target tissue.
Solution Approach 2:
The bisphosphonate acts as a mediator that facilitates targeted delivery of the therapeutic agent to bone tissue. By conjugating chloroquine to the bone-seeking bisphosphonate, the system achieves precise delivery to bone while maintaining the therapeutic benefits of chloroquine.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
BTCQ analogs effectively inhibit osteoclast formation and bone resorption, demonstrate anti-resorptive activity in humans, and reduce inflammation, offering improved therapeutic outcomes for osteoporosis and inflammatory bone diseases with reduced systemic toxicity.
Implementation Method 1
The compounds of the present invention include a novel bone-targeting chemical approach in which a drug, chloroquine (CQ), is conjugated to a non-bioactive bisphosphonate (BP)
Implementation Method 2
Carbamate linkers are cleaved by enzymatic or by hydrolytic means in the acidic microenvironment under the osteoclast ruffled border in bone resorption sites, thus releasing the active drug
Data Source
AI summary
The present invention provides compositions and methods for providing controllable local delivery of a conjugate of chloroquine (CQ) and a bisphosphonate to treat diseases characterized by abnormal bone metabolism. In certain embodiments, the invention is used as a treatment for a subject with diseases and disorders characterized by bone loss.